Head-to-head · WeighScore
FuturHealth vs Neo Soma Healthcare
The verdict
Neo Soma Healthcare takes it — 65.8/100 to 65.6/100, but only just.
Neo Soma Healthcare grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Neo Soma Healthcare is a multi-product DTC telehealth platform pairing compounded GLP-1 weight management with sexual-health and anti-aging lines. FuturHealth is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | Neo Soma Healthcare |
|---|---|---|
| WeighScore | 65.6/100 | 65.8/100 |
| Grade | C | C |
| Scorecard rank | #215 | #213 |
| Semaglutide | $199/mo (compounded) | $199/mo |
| Tirzepatide | Not disclosed | $330/mo |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #213 · C
Strengths
- LegitScript verification badge present
- Publishes the FDA compounded-medication disclaimer
- Pricing shown publicly for all 6 product lines
- Multi-product platform (GLP-1, sexual health, peptide therapies)
- First-month discount on semaglutide ($99 entry)
Where it loses points
- Pharmacy partner not named (503A vs 503B unclear)
- States served not listed — no per-state availability table
- No named medical director
- Standard semaglutide pricing ($199/mo) above the cheapest providers ($150–180/mo)
- Tirzepatide entry pricing ($330) above the cheapest providers (~$200–250/mo)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.